Latest Biologicals News

Bio-Gene Technology Limited reported a net loss of AUD 2.58 million for FY2025 while making significant strides in developing its bio-insecticides Flavocide and Qcide, securing US Department of Defense grants and expanding global partnerships.

RLF AgTech Ltd has secured $4.5 million through a discounted share placement to support its strategic growth initiatives following a robust 74% revenue increase in FY2025. The company is advancing its Australian relaunch, expanding manufacturing, and entering new Asian markets.

Cryosite Limited reported a 12% increase in revenue for FY25, driven by a 58% surge in its ultra-frozen and cryogenic segment, while deferring dividends to fund expansion plans.

Telix Pharmaceuticals reported a robust 63% increase in revenue to $390.4 million for the first half of 2025, driven by strong Illuccix sales and the acquisition of RLS Radiopharmacies. Despite this growth, the company recorded a net loss of $2.3 million, reflecting increased investments and finance costs.

ReNerve Limited has achieved a key milestone with its first sale and clinical use of a deep dermal tissue product in the US, broadening its surgical applications beyond nerve repair. This move complements its existing nerve repair portfolio and sets the stage for further product launches later this year.

Neuren Pharmaceuticals has added SYNGAP1-related disorder to its NNZ-2591 development program following encouraging pre-clinical findings, targeting a rare condition with no approved treatments.

Vitrafy Life Sciences reported a $32.7 million loss for FY25, driven by investments in its next-generation cryopreservation platform following a $35 million IPO and a $4.8 million government grant. The company is progressing commercialization efforts with key partnerships in human and animal health.

Vitrafy Life Sciences announces a leadership change with CEO Kate Munnings retiring and co-founder Brent Owens stepping up to lead the company’s next growth phase.

BPH Global has transitioned from development to early commercial sales in its Indonesian seaweed operations, securing key offtake agreements and advancing multiple R&D projects. The company also raised $609,000 in fresh capital, positioning itself for growth in sustainable biotech markets.

KNeoMedia reports steady progress toward ASX reinstatement, underpinned by successful capital raises and significant expansion of its KneoScience educational platform in partnership with the New York City Department of Education.

Cambium Bio has cleared key regulatory hurdles for its lead dry eye disease treatment, Elate Ocular, and strengthened its balance sheet with a $2.12 million placement to support upcoming Phase 3 trials.

Medallion Metals has amended terms to acquire 100% of Forrestania Nickel Operation assets, while progressing strong drilling results and financing discussions at Ravensthorpe Gold Project, positioning for a Final Investment Decision in late 2025.